Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

The state of Texas has filed a lawsuit against drug companies that produce insulin and pharmacy benefit managers (PBM), claiming there is a conspiracy to k ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The litigation comes as pharmacy benefit managers Express Scripts, CVS Caremark and Optum Rx have faced growing criticism over their role in high drug costs — including a recent lawsuit from the ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

LEBANON, Ind. (WFFT) — Eli Lilly and Company announced another $4.5 billion investment in Lebanon’s LEAP Research and ...